keyword
MENU ▼
Read by QxMD icon Read
search

Ki67 breast cancer

keyword
https://www.readbyqxmd.com/read/28237784/differences-in-ki67-expressions-between-pre-and-post-neoadjuvant-chemotherapy-specimens-might-predict-early-recurrence-of-breast-cancer
#1
Emi Tokuda, Yoshiya Horimoto, Atsushi Arakawa, Takanori Himuro, Koji Senuma, Katsuya Nakai, Mitsue Saito
The prognosis of breast cancer patients not obtaining a pathological complete response (pCR) with neoadjuvant chemotherapy (NAC) is poorer than that of pCR patients. Identifying new prognostic factors for non-pCR patients is important because fractions of this population might benefit from novel adjuvant treatments currently under development. High Ki67 expression in remnant disease after NAC has been described as a poor prognostic factor. Studies have shown that a reduction in Ki67 expression is more often observed in good responders to chemotherapy...
February 22, 2017: Human Pathology
https://www.readbyqxmd.com/read/28220627/downregulation-of-mirna-141-in-breast-cancer-cells-is-associated-with-cell-migration-and-invasion-involvement-of-anp32e-targeting
#2
Ping Li, Tao Xu, Xin Zhou, Liangying Liao, Guolian Pang, Wan Luo, Lu Han, Jiankun Zhang, Xianyong Luo, Xiaobing Xie, Kuichun Zhu
MicroRNAs (miRNAs) regulate many cellular activities, including cancer development, progression, and metastasis. Some miRNAs are involved in breast cancer (BC) migration and invasion, thus affect patients' prognosis. Microarray analysis was performed to compare miRNA expression in BC tissues, and results confirmed by qPCR. BC cell migration and invasion were studied in vitro with MDA-MB-231 cells using microplate transwell assays. miRNA targeting was investigated using luciferase assays, qPCR, and Western blot analysis in cells with overexpression of miRNA mimics...
February 21, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28218233/multi-institutional-study-of-nuclear-kifc1-as-a-biomarker-of-poor-prognosis-in-african-american-women-with-triple-negative-breast-cancer
#3
Angela Ogden, Chakravarthy Garlapati, Xiaoxian Bill Li, Ravi Chakra Turaga, Gabriela Oprea-Ilies, Nikita Wright, Shristi Bhattarai, Karuna Mittal, Ceyda Sönmez Wetherilt, Uma Krishnamurti, Michelle D Reid, Mildred Jones, Meenakshi Gupta, Remus Osan, Sonal Pattni, Ansa Riaz, Sergey Klimov, Arundhati Rao, Guilherme Cantuaria, Padmashree C G Rida, Ritu Aneja
Nuclear KIFC1 (nKIFC1) predicts worse outcomes in breast cancer, but its prognostic value within racially distinct triple-negative breast cancer (TNBC) patients is unknown. Thus, nKIFC1 expression was assessed by immunohistochemistry in 163 African American (AA) and 144 White TNBC tissue microarrays (TMAs) pooled from four hospitals. nKIFC1 correlated significantly with Ki67 in White TNBCs but not in AA TNBCs, suggesting that nKIFC1 is not merely a surrogate for proliferation in AA TNBCs. High nKIFC1 weighted index (WI) was associated with significantly worse overall survival (OS), progression-free survival (PFS), and distant metastasis-free survival (DMFS) (Hazard Ratios [HRs] = 3...
February 20, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28216075/-androgen-receptors-in-breast-cancer-expression-value-and-therapeutic-prospects
#4
REVIEW
Delphine Héquet, Slim Mzoughi, Roman Rouzier, Ernesto Guccione
Triple-negative (TN) breast cancer are characterized by lack of estrogen receptor (OR) and progesterone receptor (PR) expression, and the absence of overexpression of human epidermal growth factor receptor 2 (HER2). It is a heterogeneous group of tumors with a more pejorative prognosis than other subtypes of breast cancer. Androgen receptors (AR) are nuclear receptors whose expression varies from 80 to 85% of primary breast cancers and 60 to 75% of metastatic cancers. Among the TN breast cancers, the luminal androgen receptor (LAR) subtype expresses AR more frequently, up to 53% of the cases...
February 16, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/28212549/the-prevalence-and-clinicopathological-features-of-breast-cancer-patients-with-hepatitis-b-virus-infection-in-china
#5
He Wu, Chunxia Zhao, Vishnu Prasad Adhikari, Linjie Lu, Jianbo Huang, Yuxian Wei, Qingqing Luo, Wei Dai, Yutuan Wu, Xin Li, Kainan Wu, Ling-Quan Kong
We performed a case-control study to investigate the prevalence and clinicopathological features of breast cancer patients with hepatitis B virus (HBV) infection in China. The clinical data for 2,796 female patients with newly diagnosed, primary breast cancer were evaluated. A total of 234 breast cancer patients with HBV infection (the case group; positive for hepatitis B surface antigen [HBsAg]) and 444 breast cancer patients without HBV infection (the control group; negative for HBsAg, hepatitis B surface antibody, hepatitis B envelope antigen, hepatitis B envelope antibody, and hepatitis B core antibody) were selected for study...
February 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/28208155/pet-mr-in-invasive-ductal-breast-cancer-correlation-between-imaging-markers-and-histological-phenotype
#6
Onofrio Antonio Catalano, Gary Lloyd Horn, Alberto Signore, Carlo Iannace, Maria Lepore, Mark Vangel, Angelo Luongo, Marco Catalano, Constance Lehman, Marco Salvatore, Andrea Soricelli, Ciprian Catana, Umar Mahmood, Bruce Robert Rosen
BACKGROUND: Differences in genetics and receptor expression (phenotypes) of invasive ductal breast cancer (IDC) impact on prognosis and treatment response. Immunohistochemistry (IHC), the most used technique for IDC phenotyping, has some limitations including its invasiveness. We explored the possibility of contrast-enhanced positron emission tomography magnetic resonance (CE-FDG PET/MR) to discriminate IDC phenotypes. METHODS: 21 IDC patients with IHC assessment of oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor-2 (HER2), and antigen Ki-67 (Ki67) underwent CE-FDG PET/MR...
February 16, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28203454/mir-328-may-be-considered-as-an-oncogene-in-human-invasive-breast-carcinoma
#7
Alihossein Saberi, Amir Danyaei, Niloofar Neisi, Maryam Dastoorpoor, Mohammad Javad Tahmasbi Birgani
BACKGROUND: The recent investigations have rendered microRNAs (miRs) as a novel biomarker in cancer research. In fact, alteration in miR expression may be associated with tumor suppression, tumorigenesis, metastasis, and poor prognosis in human breast cancer (BC). OBJECTIVES: The aim of this clinical experimental study was to measure the miR-328 expression level in breast cancer tissues, at first. Then, we tried to find out any possible correlation between miR-328 and prognostic and predictive biomarkers in BC...
November 2016: Iranian Red Crescent Medical Journal
https://www.readbyqxmd.com/read/28193231/association-of-osteopontin-with-specific-prognostic-factors-and-survival-in-adjuvant-breast-cancer-trials-of-the-hellenic-cooperative-oncology-group
#8
Amanda Psyrri, Konstantine T Kalogeras, Ralph M Wirtz, George Kouvatseas, Georgia Karayannopoulou, Anna Goussia, Flora Zagouri, Elke Veltrup, Eleni Timotheadou, Helen Gogas, Angelos Koutras, Georgios Lazaridis, Christos Christodoulou, George Pentheroudakis, Panagiota Economopoulou, Apostolos Laskarakis, Petroula Arapantoni-Dadioti, Anna Batistatou, Maria Sotiropoulou, Gerasimos Aravantinos, Pavlos Papakostas, Paris Kosmidis, Dimitrios Pectasides, George Fountzilas
BACKGROUND: The shift towards an earlier diagnosis of breast cancer (BC) highlights the need for biomarkers that would identify patients at risk for relapse and metastatic spread and indicate the potential value of additional treatment strategies. Osteopontin (OPN) is a matricellular protein that has been suggested to be a potential biomarker in BC. In the present study, we used archived BC patient samples to assess the clinical utility of OPN. METHODS: Formalin-fixed paraffin-embedded tumor tissue samples from 975 patients were collected from two large phase III randomized adjuvant chemotherapy trials (HE10/97 and HE10/00) that included patients with high risk BC...
February 13, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28191804/does-alternative-and-traditional-wasam-local-cautery-therapy-facilitate-an-early-and-more-extensive-locoregional-metastasis-of-breast-cancer
#9
(no author information available yet)
INTRODUCTION: A large heterogeneous group of unproven remedies exist to treat cancer in both developed and developing countries. Some of these remedies often do more harm than good to the patients. The traditional medicine is the sum total of the knowledge, skills, and practices based on the theories, beliefs, and experiences indigenous to different cultures. The traditional medicine in Oman is based on herbal treatment and skin treatment (massage, Cupping and skin burn "cautery" treatment-known as Wasam or Kaiy)...
September 2016: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/28188752/comparison-of-five-ki67-antibodies-regarding-reproducibility-and-capacity-to-predict-prognosis-in-breast-cancer-does-the-antibody-matter
#10
Balázs Ács, Janina Kulka, K Attila Kovács, Ivett Teleki, Anna-Mária Tőkés, Ágnes Meczker, Balázs Győrffy, Lilla Madaras, Tibor Krenács, A Marcell Szász
Although several antibodies are available for immunohistochemical (IHC) detection of Ki-67, even the most commonly used MIB-1 has not been validated yet. Our aim was to compare 5 commercially available antibodies for detection of Ki-67 in terms of agreement and their ability in predicting prognosis of breast cancer. Tissue microarrays were constructed from 378 breast cancer patients' representative formalin-fixed paraffin-embedded tumor blocks. Five antibodies were used to detect Ki-67 expression: MIB-1-using chromogenic detection and immunofluorescent labeled (IF) MIB1-, SP-6, 30-9, poly and B56...
February 8, 2017: Human Pathology
https://www.readbyqxmd.com/read/28187885/automated-characterization-and-counting-of-ki-67-protein-for-breast-cancer-prognosis-a-quantitative-immunohistochemistry-approach
#11
Tushar Mungle, Suman Tewary, Indu Arun, Bijan Basak, Sanjit Agarwal, Rosina Ahmed, Sanjoy Chatterjee, Asok Kumar Maity, Chandan Chakraborty
Ki-67 protein expression plays an important role in predicting the proliferative status of tumour cells and deciding the future course of therapy in breast cancer. Immunohistochemical (IHC) determination of Ki-67 score or labelling index, by estimating the fraction of Ki67 positively stained tumour cells, is the most widely practiced method to assess tumour proliferation (Dowsett et al. 2011). Accurate manual counting of these cells (specifically nuclei) due to complex and dense distribution of cells, therefore, becomes critical and presents a major challenge to pathologists...
February 2017: Computer Methods and Programs in Biomedicine
https://www.readbyqxmd.com/read/28187031/x-ray-of-excised-cancerous-breast-tissue-does-not-affect-clinical-biomarker-expression
#12
Isaac E Lloyd, Alana L Welm, Yoko DeRose, Leigh A Neumayer, Jessica L Kohan, Elisabeth M Malmberg, Mohamed E Salama, Rachel E Factor
CONTEXT: College of American Pathologists (CAP) and the American Society of Clinical Oncology have emphasized the need to reduce preanalytic variables for evaluating predictive biomarker expression in breast cancer. Postoperative x-ray of excised breast tissue is commonplace, yet is a variable that has not been investigated previously. We asked whether such radiation affects expression of relevant biomarkers. DESIGN: A previous study found that human breast cancers grown in mice demonstrate the same immunohistochemical and molecular profiles as the original tumors...
February 9, 2017: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/28155606/clinical-utility-of-neoadjuvant-endocrine-therapy-for-hormone-receptor-positive-breast-cancer
#13
Hans-Christian Kolberg, Bahriye Aktas, Cornelia Liedtke
Primary endocrine therapy is an option in cases of hormone receptor positive and HER2 negative non-metastatic breast cancer. Aromatase inhibitors are considered therapy of choice in postmenopausal patients. In premenopausal patients aromatase inhibitors in combination with LHRH-analogues are regarded superior to tamoxifen. Three different settings have to be discriminated: • Patients too frail for surgery are candidates for primary endocrine therapy in order to control the disease. Treatment duration is determined by the course of the disease...
February 1, 2017: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/28152473/combination-of-arabinogalactan-and-curcumin-induces-apoptosis-in-breast-cancer-cells-in-vitro-and-inhibits-tumor-growth-via-overexpression-of-p53-level-in-vivo
#14
Hassan Moghtaderi, Houri Sepehri, Farnoosh Attari
PURPOSE: Increased mortality associated with breast cancer in women has spurred the studies to develop new drugs. Arabinogalactan (AG) and curcumin (Cur) are two natural products broadly explored in cancer therapy. Our major goal in the current study was to assess anticancer properties of combination these reagents in vitro on human breast cancer cells and in vivo utilizing animal model of breast cancer. EXPERIMENTAL DESIGN: We evaluated cell proliferation, apoptosis, cell cycle, and protein expression in vitro on MDA-MB-231 human breast cancer cells...
January 29, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28124285/fgd5-amplification-in-breast-cancer-patients-is-associated-with-tumour-proliferation-and-a-poorer-prognosis
#15
Marit Valla, Monica Jernberg Engstrøm, Borgny Ytterhus, Åse Kristin Skain Hansen, Lars Andreas Akslen, Lars Johan Vatten, Signe Opdahl, Anna Mary Bofin
PURPOSE: Proliferation is a hallmark of cancer. Using a combined genomic approach, FGD5 amplification has been identified as a driver of proliferation in Luminal breast cancer. We aimed to describe FGD5 copy number change in breast cancer, and to assess a possible association with tumour proliferation and prognosis. METHODS: We used fluorescence in situ hybridization targeting FGD5 and chromosome 3 centromere (CEP3) on formalin-fixed, paraffin-embedded tissue from 430 primary breast cancers and 108 lymph node metastases, from a cohort of Norwegian breast cancer patients...
April 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28100469/immunohistochemical-phenotype-of-breast-cancer-during-25-year-follow-up-of-the-royal-marsden-tamoxifen-prevention-trial
#16
Simone Detre, Susan Ashley, Kabir Mohammed, Ian E Smith, Trevor Powles, Mitch Dowsett
Background The randomized double-blinded Royal Marsden Tamoxifen Breast Cancer Prevention Trial in healthy high-risk women started in 1986 and is still blinded. 2471 eligible participants were randomly assigned to tamoxifen (20mg/day) or placebo for 8 years. Analysis in 2006 showed a 30% risk reduction of ER-positive invasive breast cancer mostly in the post treatment period. Biomarker analysis in this population may identify any sub-group specific preventive effects tamoxifen. Methods After a median follow-up of 18...
January 18, 2017: Cancer Prevention Research
https://www.readbyqxmd.com/read/28089283/myc-amplification-as-a-predictive-factor-of-complete-pathologic-response-to-docetaxel-based-neoadjuvant-chemotherapy-for-breast-cancer
#17
Cynthia Brito Lins Pereira, Mariana Ferreira Leal, Eliana Saul Furquim Werneck Abdelhay, Sâmia Demachki, Paulo Pimentel Assumpção, Mirian Carvalho de Souza, Caroline Aquino Moreira-Nunes, Adriana Michiko da Silva Tanaka, Marília Cardoso Smith, Rommel Rodríguez Burbano
BACKGROUND: Neoadjuvant chemotherapy is a standard treatment for stage II and III breast cancer. The identification of biomarkers that may help in the prediction of response to neoadjuvant therapies is necessary for a more precise definition of the best drug or drug combination to induce a better response. MATERIAL AND METHODS: We assessed the role of Ki67, hormone receptors expression, HER2, MYC genes and their protein status, and KRAS codon 12 mutations as predictor factors of pathologic response to anthracycline-cyclophosphamide (AC) followed by taxane docetaxel (T) neoadjuvant chemotherapy (AC+T regimen) in 51 patients with invasive ductal breast cancer...
December 24, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28078851/mechanism-of-serum-mir-21-in-the-pathogenesis-of-familial-and-triple-negative-breast-cancer
#18
L Yang, Y Feng, P Qi, S Xu, Y Zhou
The aim of this study was to clarify the mechanism of miR-21 in familial and triple-negative breast cancer (TNBC) by exploring the expression of serum miR-21. The sera were collected from healthy women at high risk of breast cancer. miR-39 was employed as the external reference, and real-time fluorescence quantitative PCR was used to detect the expression of serum miR-21 in 77 subjects. The miR-21 expression of the familial breast cancer group, TNBC group, and breast cancer high risk group were significantly higher than those in the normal control group and other breast cancer groups (P less than 0...
October 2016: Journal of Biological Regulators and Homeostatic Agents
https://www.readbyqxmd.com/read/28076434/diabetes-and-breast-cancer-subtypes
#19
Heleen K Bronsveld, Vibeke Jensen, Pernille Vahl, Marie L De Bruin, Sten Cornelissen, Joyce Sanders, Anssi Auvinen, Jari Haukka, Morten Andersen, Peter Vestergaard, Marjanka K Schmidt
BACKGROUND: Women with diabetes have a worse survival after breast cancer diagnosis compared to women without diabetes. This may be due to a different etiological profile, leading to the development of more aggressive breast cancer subtypes. Our aim was to investigate whether insulin and non-insulin treated women with diabetes develop specific clinicopathological breast cancer subtypes compared to women without diabetes. METHODS AND FINDINGS: This cross-sectional study included randomly selected patients with invasive breast cancer diagnosed in 2000-2010...
2017: PloS One
https://www.readbyqxmd.com/read/28065411/ki67-assessment-in-breast-cancer-an-update
#20
Frederique Penault-Llorca, Nina Radosevic-Robin
Although immunohistochemical detection of the Ki67 antigen has been used for many years to assess cancer proliferation, this marker is still not recommended for routine use in clinical management of breast cancer. The major reason for this situation is a lack of a standardised procedure for Ki67 assessment as well as persistence of several issues of debate with regards to the Ki67 assay interpretation and the marker's clinical utility. Nowadays Ki67 assessment is principally used for estimation of prognosis and guiding the decision on adjuvant treatment choice, as well as for prediction of response to neoadjuvant treatment in ER+/HER2- breast cancer...
February 2017: Pathology
keyword
keyword
72753
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"